RIPK3-IN-1 is a RIPK3 type II DFG-out inhibitor with an IC 50 of 9.1 nM. RIPK3-IN-1 inhibits RIPK1 and RIPK2 with IC 50 s of 5.5 and >10 μM. RIPK3-IN-1 is also a c-Met kinase inhibitor with an IC 50 of 1.1 μM In Vitro RIPK3-IN-1 (Compound 18) also inhibits ABL, BRAF/V599E, MAP4K3, and SRC with IC 50 s of 0.37, 0.15, 0.012, and 0.075 μM, respectively. Necroptosis is a programmed form of cell death and has been associated with a variety of diseases, including ischemia reperfusion injury, neurodegenerative disorders, pancreatic cancer, and autoimmune diseases such as inflammatory bowel disease (IBD). Upon stimulation of death receptors (such as the family of TNF receptors), signaling can initiate a necroptotic cell death process. This involves formation of a necrosome, which includes receptor interacting protein kinases 1 and 3 (RIPK1, RIPK3) in a cytosolic complex. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 9.1 nM (RIPK3), 5.5 μM (RIPK1), >10 μM (RIPK2)
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
RIPK3-IN-1
CAS number：2361139-70-8 molecular formula：C29H25FN4O4
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 2361139-70-8 | molecular formula | C29H25FN4O4 |
| molecular weight | 512.53 g/mol | Exact mass | ≥98% |
| PSA | 101.000 Ų | logp | 4.200 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
